Vancouver-based Bold Therapeutics is partnering with the University of Ottawa, Canada, to explore the potential efficacy of its anti-viral BOLD-100 against Covid-19.
This drug inhibits the stress-induced upregulation of GRP78, which has a role in host recognition, viral entry and viral replication.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bold has been investigating this anti-viral in combination with chemotherapy and other oncology agents in gastrointestinal cancer; the company is focused on overcoming drug resistance in cancer.
University of Ottawa faculty professor of medicine and Canada Research molecular virology and intrinsic immunity chair Dr Marc-André Langlois noted: “We will be using our lentiviral-based infection system, derived from HIV, equipped with the SARS-CoV-2 (COVID-19) spike, to study the impact of BOLD-100 on viral entry.
“There is an urgent need for novel antiviral agents effective against COVID-19 and related pathogens, and we look forward to advancing our understanding of the role that GRP78 plays in viral entry.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
